nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—breast cancer	0.218	1	CbGaD
Terazosin—ABCB1—Toremifene—breast cancer	0.0664	0.223	CbGbCtD
Terazosin—ABCB1—Lapatinib—breast cancer	0.0484	0.162	CbGbCtD
Terazosin—ABCB1—Vinorelbine—breast cancer	0.0269	0.0901	CbGbCtD
Terazosin—ABCB1—Tamoxifen—breast cancer	0.0243	0.0813	CbGbCtD
Terazosin—ABCB1—Mitoxantrone—breast cancer	0.0237	0.0793	CbGbCtD
Terazosin—ABCB1—Gemcitabine—breast cancer	0.0209	0.0701	CbGbCtD
Terazosin—ABCB1—Paclitaxel—breast cancer	0.0189	0.0633	CbGbCtD
Terazosin—ABCB1—Irinotecan—breast cancer	0.0186	0.0624	CbGbCtD
Terazosin—ABCB1—Vinblastine—breast cancer	0.0166	0.0555	CbGbCtD
Terazosin—ABCB1—Docetaxel—breast cancer	0.0137	0.0458	CbGbCtD
Terazosin—ABCB1—Doxorubicin—breast cancer	0.0102	0.0341	CbGbCtD
Terazosin—ABCB1—Methotrexate—breast cancer	0.00986	0.033	CbGbCtD
Terazosin—Prazosin—MT3—breast cancer	0.00449	0.55	CrCbGaD
Terazosin—Prazosin—ABCG2—breast cancer	0.000891	0.109	CrCbGaD
Terazosin—Alfuzosin—CYP3A4—breast cancer	0.000744	0.0911	CrCbGaD
Terazosin—Prazosin—CYP1A1—breast cancer	0.000698	0.0855	CrCbGaD
Terazosin—Doxazosin—CYP2D6—breast cancer	0.000564	0.0691	CrCbGaD
Terazosin—KCNH6—uterus—breast cancer	0.000512	0.109	CbGeAlD
Terazosin—KCNH6—female reproductive system—breast cancer	0.00046	0.0977	CbGeAlD
Terazosin—Doxazosin—ABCB1—breast cancer	0.000403	0.0493	CrCbGaD
Terazosin—Prazosin—ABCB1—breast cancer	0.000371	0.0455	CrCbGaD
Terazosin—ADRA1D—epithelium—breast cancer	0.000343	0.0728	CbGeAlD
Terazosin—KCNH2—nipple—breast cancer	0.000283	0.06	CbGeAlD
Terazosin—ADRA1D—female reproductive system—breast cancer	0.000255	0.0541	CbGeAlD
Terazosin—ADRA1D—endocrine gland—breast cancer	0.000216	0.0458	CbGeAlD
Terazosin—ADRA1A—epithelium—breast cancer	0.000197	0.0418	CbGeAlD
Terazosin—KCNH2—endometrium—breast cancer	0.000171	0.0362	CbGeAlD
Terazosin—ADRA1A—adipose tissue—breast cancer	0.000159	0.0338	CbGeAlD
Terazosin—KCNH2—uterus—breast cancer	0.000157	0.0334	CbGeAlD
Terazosin—KCNH2—pituitary gland—breast cancer	0.000155	0.0328	CbGeAlD
Terazosin—ADRA1A—adrenal gland—breast cancer	0.000143	0.0303	CbGeAlD
Terazosin—KCNH2—female reproductive system—breast cancer	0.000141	0.03	CbGeAlD
Terazosin—KCNH2—adrenal gland—breast cancer	0.000138	0.0293	CbGeAlD
Terazosin—KCNH2—bone marrow—breast cancer	0.000134	0.0283	CbGeAlD
Terazosin—KCNH2—female gonad—breast cancer	0.000129	0.0273	CbGeAlD
Terazosin—ADRA1A—endocrine gland—breast cancer	0.000124	0.0263	CbGeAlD
Terazosin—KCNH2—endocrine gland—breast cancer	0.00012	0.0254	CbGeAlD
Terazosin—Pharyngitis—Epirubicin—breast cancer	0.000103	0.000287	CcSEcCtD
Terazosin—Sweating—Doxorubicin—breast cancer	0.000103	0.000285	CcSEcCtD
Terazosin—Hyperhidrosis—Capecitabine—breast cancer	0.000103	0.000285	CcSEcCtD
Terazosin—Oedema peripheral—Epirubicin—breast cancer	0.000102	0.000284	CcSEcCtD
Terazosin—Hypotension—Docetaxel—breast cancer	0.000102	0.000284	CcSEcCtD
Terazosin—ABCB1—embryo—breast cancer	0.000102	0.0217	CbGeAlD
Terazosin—Body temperature increased—Paclitaxel—breast cancer	0.000102	0.000284	CcSEcCtD
Terazosin—Abdominal pain—Paclitaxel—breast cancer	0.000102	0.000284	CcSEcCtD
Terazosin—Epistaxis—Doxorubicin—breast cancer	0.000101	0.000281	CcSEcCtD
Terazosin—Anorexia—Capecitabine—breast cancer	0.000101	0.000281	CcSEcCtD
Terazosin—Vomiting—Irinotecan—breast cancer	0.000101	0.00028	CcSEcCtD
Terazosin—Vomiting—Mitoxantrone—breast cancer	0.000101	0.00028	CcSEcCtD
Terazosin—Sinusitis—Doxorubicin—breast cancer	0.000101	0.000279	CcSEcCtD
Terazosin—Dizziness—Fluorouracil—breast cancer	0.0001	0.000279	CcSEcCtD
Terazosin—Visual impairment—Epirubicin—breast cancer	0.0001	0.000278	CcSEcCtD
Terazosin—Rash—Irinotecan—breast cancer	0.0001	0.000277	CcSEcCtD
Terazosin—Rash—Mitoxantrone—breast cancer	0.0001	0.000277	CcSEcCtD
Terazosin—Dermatitis—Irinotecan—breast cancer	9.99e-05	0.000277	CcSEcCtD
Terazosin—Dermatitis—Mitoxantrone—breast cancer	9.99e-05	0.000277	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Docetaxel—breast cancer	9.98e-05	0.000277	CcSEcCtD
Terazosin—Headache—Irinotecan—breast cancer	9.93e-05	0.000276	CcSEcCtD
Terazosin—Headache—Mitoxantrone—breast cancer	9.93e-05	0.000276	CcSEcCtD
Terazosin—Hypotension—Capecitabine—breast cancer	9.91e-05	0.000275	CcSEcCtD
Terazosin—Insomnia—Docetaxel—breast cancer	9.91e-05	0.000275	CcSEcCtD
Terazosin—Paraesthesia—Docetaxel—breast cancer	9.84e-05	0.000273	CcSEcCtD
Terazosin—Vomiting—Gemcitabine—breast cancer	9.82e-05	0.000273	CcSEcCtD
Terazosin—Dyspnoea—Docetaxel—breast cancer	9.77e-05	0.000271	CcSEcCtD
Terazosin—Somnolence—Docetaxel—breast cancer	9.74e-05	0.00027	CcSEcCtD
Terazosin—Rash—Gemcitabine—breast cancer	9.74e-05	0.00027	CcSEcCtD
Terazosin—Dermatitis—Gemcitabine—breast cancer	9.73e-05	0.00027	CcSEcCtD
Terazosin—Eye disorder—Epirubicin—breast cancer	9.72e-05	0.00027	CcSEcCtD
Terazosin—Tinnitus—Epirubicin—breast cancer	9.7e-05	0.000269	CcSEcCtD
Terazosin—Malnutrition—Methotrexate—breast cancer	9.68e-05	0.000269	CcSEcCtD
Terazosin—Headache—Gemcitabine—breast cancer	9.67e-05	0.000269	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Capecitabine—breast cancer	9.67e-05	0.000268	CcSEcCtD
Terazosin—Vomiting—Fluorouracil—breast cancer	9.65e-05	0.000268	CcSEcCtD
Terazosin—Rhinitis—Doxorubicin—breast cancer	9.65e-05	0.000268	CcSEcCtD
Terazosin—Dyspepsia—Docetaxel—breast cancer	9.65e-05	0.000268	CcSEcCtD
Terazosin—Insomnia—Capecitabine—breast cancer	9.6e-05	0.000266	CcSEcCtD
Terazosin—Rash—Fluorouracil—breast cancer	9.57e-05	0.000266	CcSEcCtD
Terazosin—Dermatitis—Fluorouracil—breast cancer	9.56e-05	0.000265	CcSEcCtD
Terazosin—Pharyngitis—Doxorubicin—breast cancer	9.55e-05	0.000265	CcSEcCtD
Terazosin—Paraesthesia—Capecitabine—breast cancer	9.53e-05	0.000264	CcSEcCtD
Terazosin—Decreased appetite—Docetaxel—breast cancer	9.53e-05	0.000264	CcSEcCtD
Terazosin—Hypersensitivity—Paclitaxel—breast cancer	9.53e-05	0.000264	CcSEcCtD
Terazosin—Headache—Fluorouracil—breast cancer	9.51e-05	0.000264	CcSEcCtD
Terazosin—Oedema peripheral—Doxorubicin—breast cancer	9.48e-05	0.000263	CcSEcCtD
Terazosin—Dysgeusia—Methotrexate—breast cancer	9.48e-05	0.000263	CcSEcCtD
Terazosin—Dyspnoea—Capecitabine—breast cancer	9.46e-05	0.000263	CcSEcCtD
Terazosin—Fatigue—Docetaxel—breast cancer	9.45e-05	0.000262	CcSEcCtD
Terazosin—Nausea—Mitoxantrone—breast cancer	9.42e-05	0.000261	CcSEcCtD
Terazosin—Nausea—Irinotecan—breast cancer	9.42e-05	0.000261	CcSEcCtD
Terazosin—Pain—Docetaxel—breast cancer	9.37e-05	0.00026	CcSEcCtD
Terazosin—Constipation—Docetaxel—breast cancer	9.37e-05	0.00026	CcSEcCtD
Terazosin—Back pain—Methotrexate—breast cancer	9.36e-05	0.00026	CcSEcCtD
Terazosin—Dyspepsia—Capecitabine—breast cancer	9.34e-05	0.000259	CcSEcCtD
Terazosin—Arrhythmia—Epirubicin—breast cancer	9.29e-05	0.000258	CcSEcCtD
Terazosin—Visual impairment—Doxorubicin—breast cancer	9.28e-05	0.000257	CcSEcCtD
Terazosin—Asthenia—Paclitaxel—breast cancer	9.28e-05	0.000257	CcSEcCtD
Terazosin—Decreased appetite—Capecitabine—breast cancer	9.22e-05	0.000256	CcSEcCtD
Terazosin—Nausea—Gemcitabine—breast cancer	9.17e-05	0.000255	CcSEcCtD
Terazosin—Fatigue—Capecitabine—breast cancer	9.15e-05	0.000254	CcSEcCtD
Terazosin—Pruritus—Paclitaxel—breast cancer	9.15e-05	0.000254	CcSEcCtD
Terazosin—Vision blurred—Methotrexate—breast cancer	9.12e-05	0.000253	CcSEcCtD
Terazosin—Constipation—Capecitabine—breast cancer	9.07e-05	0.000252	CcSEcCtD
Terazosin—Pain—Capecitabine—breast cancer	9.07e-05	0.000252	CcSEcCtD
Terazosin—Malnutrition—Epirubicin—breast cancer	9.06e-05	0.000251	CcSEcCtD
Terazosin—Feeling abnormal—Docetaxel—breast cancer	9.03e-05	0.000251	CcSEcCtD
Terazosin—Nausea—Fluorouracil—breast cancer	9.02e-05	0.00025	CcSEcCtD
Terazosin—Eye disorder—Doxorubicin—breast cancer	9e-05	0.00025	CcSEcCtD
Terazosin—Ill-defined disorder—Methotrexate—breast cancer	8.98e-05	0.000249	CcSEcCtD
Terazosin—Tinnitus—Doxorubicin—breast cancer	8.98e-05	0.000249	CcSEcCtD
Terazosin—Gastrointestinal pain—Docetaxel—breast cancer	8.96e-05	0.000249	CcSEcCtD
Terazosin—Flatulence—Epirubicin—breast cancer	8.92e-05	0.000248	CcSEcCtD
Terazosin—Tension—Epirubicin—breast cancer	8.89e-05	0.000247	CcSEcCtD
Terazosin—Dysgeusia—Epirubicin—breast cancer	8.87e-05	0.000246	CcSEcCtD
Terazosin—Diarrhoea—Paclitaxel—breast cancer	8.85e-05	0.000246	CcSEcCtD
Terazosin—Nervousness—Epirubicin—breast cancer	8.8e-05	0.000244	CcSEcCtD
Terazosin—Back pain—Epirubicin—breast cancer	8.76e-05	0.000243	CcSEcCtD
Terazosin—Feeling abnormal—Capecitabine—breast cancer	8.74e-05	0.000243	CcSEcCtD
Terazosin—Malaise—Methotrexate—breast cancer	8.73e-05	0.000242	CcSEcCtD
Terazosin—Vertigo—Methotrexate—breast cancer	8.69e-05	0.000241	CcSEcCtD
Terazosin—Gastrointestinal pain—Capecitabine—breast cancer	8.68e-05	0.000241	CcSEcCtD
Terazosin—Body temperature increased—Docetaxel—breast cancer	8.66e-05	0.00024	CcSEcCtD
Terazosin—Abdominal pain—Docetaxel—breast cancer	8.66e-05	0.00024	CcSEcCtD
Terazosin—Arrhythmia—Doxorubicin—breast cancer	8.6e-05	0.000239	CcSEcCtD
Terazosin—Dizziness—Paclitaxel—breast cancer	8.55e-05	0.000237	CcSEcCtD
Terazosin—Vision blurred—Epirubicin—breast cancer	8.54e-05	0.000237	CcSEcCtD
Terazosin—Cough—Methotrexate—breast cancer	8.44e-05	0.000234	CcSEcCtD
Terazosin—Ill-defined disorder—Epirubicin—breast cancer	8.4e-05	0.000233	CcSEcCtD
Terazosin—Body temperature increased—Capecitabine—breast cancer	8.39e-05	0.000233	CcSEcCtD
Terazosin—Abdominal pain—Capecitabine—breast cancer	8.39e-05	0.000233	CcSEcCtD
Terazosin—Convulsion—Methotrexate—breast cancer	8.38e-05	0.000233	CcSEcCtD
Terazosin—Malnutrition—Doxorubicin—breast cancer	8.38e-05	0.000233	CcSEcCtD
Terazosin—ABCB1—epithelium—breast cancer	8.35e-05	0.0177	CbGeAlD
Terazosin—KCNH2—lymph node—breast cancer	8.28e-05	0.0176	CbGeAlD
Terazosin—Flatulence—Doxorubicin—breast cancer	8.26e-05	0.000229	CcSEcCtD
Terazosin—Myalgia—Methotrexate—breast cancer	8.24e-05	0.000229	CcSEcCtD
Terazosin—Arthralgia—Methotrexate—breast cancer	8.24e-05	0.000229	CcSEcCtD
Terazosin—Chest pain—Methotrexate—breast cancer	8.24e-05	0.000229	CcSEcCtD
Terazosin—Tension—Doxorubicin—breast cancer	8.22e-05	0.000228	CcSEcCtD
Terazosin—Vomiting—Paclitaxel—breast cancer	8.22e-05	0.000228	CcSEcCtD
Terazosin—Dysgeusia—Doxorubicin—breast cancer	8.21e-05	0.000228	CcSEcCtD
Terazosin—Malaise—Epirubicin—breast cancer	8.17e-05	0.000227	CcSEcCtD
Terazosin—Rash—Paclitaxel—breast cancer	8.15e-05	0.000226	CcSEcCtD
Terazosin—Dermatitis—Paclitaxel—breast cancer	8.14e-05	0.000226	CcSEcCtD
Terazosin—Discomfort—Methotrexate—breast cancer	8.14e-05	0.000226	CcSEcCtD
Terazosin—Nervousness—Doxorubicin—breast cancer	8.14e-05	0.000226	CcSEcCtD
Terazosin—Vertigo—Epirubicin—breast cancer	8.14e-05	0.000226	CcSEcCtD
Terazosin—Syncope—Epirubicin—breast cancer	8.12e-05	0.000225	CcSEcCtD
Terazosin—Back pain—Doxorubicin—breast cancer	8.11e-05	0.000225	CcSEcCtD
Terazosin—Headache—Paclitaxel—breast cancer	8.1e-05	0.000225	CcSEcCtD
Terazosin—Hypersensitivity—Docetaxel—breast cancer	8.07e-05	0.000224	CcSEcCtD
Terazosin—Palpitations—Epirubicin—breast cancer	8e-05	0.000222	CcSEcCtD
Terazosin—Confusional state—Methotrexate—breast cancer	7.96e-05	0.000221	CcSEcCtD
Terazosin—Loss of consciousness—Epirubicin—breast cancer	7.96e-05	0.000221	CcSEcCtD
Terazosin—Cough—Epirubicin—breast cancer	7.9e-05	0.000219	CcSEcCtD
Terazosin—Anaphylactic shock—Methotrexate—breast cancer	7.9e-05	0.000219	CcSEcCtD
Terazosin—Vision blurred—Doxorubicin—breast cancer	7.9e-05	0.000219	CcSEcCtD
Terazosin—Asthenia—Docetaxel—breast cancer	7.86e-05	0.000218	CcSEcCtD
Terazosin—Convulsion—Epirubicin—breast cancer	7.85e-05	0.000218	CcSEcCtD
Terazosin—Hypersensitivity—Capecitabine—breast cancer	7.82e-05	0.000217	CcSEcCtD
Terazosin—Ill-defined disorder—Doxorubicin—breast cancer	7.78e-05	0.000216	CcSEcCtD
Terazosin—Pruritus—Docetaxel—breast cancer	7.75e-05	0.000215	CcSEcCtD
Terazosin—Thrombocytopenia—Methotrexate—breast cancer	7.73e-05	0.000215	CcSEcCtD
Terazosin—Myalgia—Epirubicin—breast cancer	7.71e-05	0.000214	CcSEcCtD
Terazosin—Arthralgia—Epirubicin—breast cancer	7.71e-05	0.000214	CcSEcCtD
Terazosin—Chest pain—Epirubicin—breast cancer	7.71e-05	0.000214	CcSEcCtD
Terazosin—Anxiety—Epirubicin—breast cancer	7.68e-05	0.000213	CcSEcCtD
Terazosin—Nausea—Paclitaxel—breast cancer	7.68e-05	0.000213	CcSEcCtD
Terazosin—Hyperhidrosis—Methotrexate—breast cancer	7.64e-05	0.000212	CcSEcCtD
Terazosin—Discomfort—Epirubicin—breast cancer	7.62e-05	0.000211	CcSEcCtD
Terazosin—Asthenia—Capecitabine—breast cancer	7.61e-05	0.000211	CcSEcCtD
Terazosin—Malaise—Doxorubicin—breast cancer	7.56e-05	0.00021	CcSEcCtD
Terazosin—Dry mouth—Epirubicin—breast cancer	7.54e-05	0.000209	CcSEcCtD
Terazosin—Vertigo—Doxorubicin—breast cancer	7.53e-05	0.000209	CcSEcCtD
Terazosin—Anorexia—Methotrexate—breast cancer	7.53e-05	0.000209	CcSEcCtD
Terazosin—Syncope—Doxorubicin—breast cancer	7.51e-05	0.000209	CcSEcCtD
Terazosin—Pruritus—Capecitabine—breast cancer	7.51e-05	0.000208	CcSEcCtD
Terazosin—Diarrhoea—Docetaxel—breast cancer	7.5e-05	0.000208	CcSEcCtD
Terazosin—ABCB1—endometrium—breast cancer	7.49e-05	0.0159	CbGeAlD
Terazosin—Confusional state—Epirubicin—breast cancer	7.45e-05	0.000207	CcSEcCtD
Terazosin—Palpitations—Doxorubicin—breast cancer	7.41e-05	0.000206	CcSEcCtD
Terazosin—Anaphylactic shock—Epirubicin—breast cancer	7.39e-05	0.000205	CcSEcCtD
Terazosin—Oedema—Epirubicin—breast cancer	7.39e-05	0.000205	CcSEcCtD
Terazosin—Hypotension—Methotrexate—breast cancer	7.38e-05	0.000205	CcSEcCtD
Terazosin—Loss of consciousness—Doxorubicin—breast cancer	7.37e-05	0.000204	CcSEcCtD
Terazosin—Cough—Doxorubicin—breast cancer	7.31e-05	0.000203	CcSEcCtD
Terazosin—Shock—Epirubicin—breast cancer	7.27e-05	0.000202	CcSEcCtD
Terazosin—Convulsion—Doxorubicin—breast cancer	7.26e-05	0.000202	CcSEcCtD
Terazosin—Diarrhoea—Capecitabine—breast cancer	7.26e-05	0.000201	CcSEcCtD
Terazosin—Dizziness—Docetaxel—breast cancer	7.25e-05	0.000201	CcSEcCtD
Terazosin—Thrombocytopenia—Epirubicin—breast cancer	7.24e-05	0.000201	CcSEcCtD
Terazosin—Tachycardia—Epirubicin—breast cancer	7.21e-05	0.0002	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Methotrexate—breast cancer	7.2e-05	0.0002	CcSEcCtD
Terazosin—Hyperhidrosis—Epirubicin—breast cancer	7.15e-05	0.000198	CcSEcCtD
Terazosin—Insomnia—Methotrexate—breast cancer	7.14e-05	0.000198	CcSEcCtD
Terazosin—Myalgia—Doxorubicin—breast cancer	7.13e-05	0.000198	CcSEcCtD
Terazosin—Chest pain—Doxorubicin—breast cancer	7.13e-05	0.000198	CcSEcCtD
Terazosin—Arthralgia—Doxorubicin—breast cancer	7.13e-05	0.000198	CcSEcCtD
Terazosin—Anxiety—Doxorubicin—breast cancer	7.11e-05	0.000197	CcSEcCtD
Terazosin—Paraesthesia—Methotrexate—breast cancer	7.09e-05	0.000197	CcSEcCtD
Terazosin—Discomfort—Doxorubicin—breast cancer	7.05e-05	0.000196	CcSEcCtD
Terazosin—Anorexia—Epirubicin—breast cancer	7.05e-05	0.000196	CcSEcCtD
Terazosin—Dyspnoea—Methotrexate—breast cancer	7.04e-05	0.000195	CcSEcCtD
Terazosin—Somnolence—Methotrexate—breast cancer	7.02e-05	0.000195	CcSEcCtD
Terazosin—Dizziness—Capecitabine—breast cancer	7.02e-05	0.000195	CcSEcCtD
Terazosin—Dry mouth—Doxorubicin—breast cancer	6.98e-05	0.000194	CcSEcCtD
Terazosin—Vomiting—Docetaxel—breast cancer	6.97e-05	0.000193	CcSEcCtD
Terazosin—Dyspepsia—Methotrexate—breast cancer	6.95e-05	0.000193	CcSEcCtD
Terazosin—Rash—Docetaxel—breast cancer	6.91e-05	0.000192	CcSEcCtD
Terazosin—Hypotension—Epirubicin—breast cancer	6.91e-05	0.000192	CcSEcCtD
Terazosin—ABCB1—uterus—breast cancer	6.9e-05	0.0146	CbGeAlD
Terazosin—Dermatitis—Docetaxel—breast cancer	6.9e-05	0.000192	CcSEcCtD
Terazosin—Confusional state—Doxorubicin—breast cancer	6.9e-05	0.000191	CcSEcCtD
Terazosin—Decreased appetite—Methotrexate—breast cancer	6.87e-05	0.000191	CcSEcCtD
Terazosin—Headache—Docetaxel—breast cancer	6.87e-05	0.000191	CcSEcCtD
Terazosin—Anaphylactic shock—Doxorubicin—breast cancer	6.84e-05	0.00019	CcSEcCtD
Terazosin—Oedema—Doxorubicin—breast cancer	6.84e-05	0.00019	CcSEcCtD
Terazosin—Fatigue—Methotrexate—breast cancer	6.81e-05	0.000189	CcSEcCtD
Terazosin—ABCB1—pituitary gland—breast cancer	6.78e-05	0.0144	CbGeAlD
Terazosin—Pain—Methotrexate—breast cancer	6.75e-05	0.000187	CcSEcCtD
Terazosin—ABCB1—adipose tissue—breast cancer	6.75e-05	0.0143	CbGeAlD
Terazosin—Vomiting—Capecitabine—breast cancer	6.75e-05	0.000187	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Epirubicin—breast cancer	6.73e-05	0.000187	CcSEcCtD
Terazosin—Shock—Doxorubicin—breast cancer	6.73e-05	0.000187	CcSEcCtD
Terazosin—Thrombocytopenia—Doxorubicin—breast cancer	6.7e-05	0.000186	CcSEcCtD
Terazosin—Rash—Capecitabine—breast cancer	6.69e-05	0.000186	CcSEcCtD
Terazosin—Insomnia—Epirubicin—breast cancer	6.69e-05	0.000186	CcSEcCtD
Terazosin—Dermatitis—Capecitabine—breast cancer	6.68e-05	0.000186	CcSEcCtD
Terazosin—Tachycardia—Doxorubicin—breast cancer	6.67e-05	0.000185	CcSEcCtD
Terazosin—Headache—Capecitabine—breast cancer	6.65e-05	0.000184	CcSEcCtD
Terazosin—Paraesthesia—Epirubicin—breast cancer	6.64e-05	0.000184	CcSEcCtD
Terazosin—Hyperhidrosis—Doxorubicin—breast cancer	6.61e-05	0.000184	CcSEcCtD
Terazosin—Dyspnoea—Epirubicin—breast cancer	6.59e-05	0.000183	CcSEcCtD
Terazosin—Somnolence—Epirubicin—breast cancer	6.57e-05	0.000182	CcSEcCtD
Terazosin—Anorexia—Doxorubicin—breast cancer	6.52e-05	0.000181	CcSEcCtD
Terazosin—Nausea—Docetaxel—breast cancer	6.51e-05	0.000181	CcSEcCtD
Terazosin—Feeling abnormal—Methotrexate—breast cancer	6.51e-05	0.000181	CcSEcCtD
Terazosin—Dyspepsia—Epirubicin—breast cancer	6.51e-05	0.000181	CcSEcCtD
Terazosin—Gastrointestinal pain—Methotrexate—breast cancer	6.46e-05	0.000179	CcSEcCtD
Terazosin—Decreased appetite—Epirubicin—breast cancer	6.43e-05	0.000178	CcSEcCtD
Terazosin—Hypotension—Doxorubicin—breast cancer	6.39e-05	0.000177	CcSEcCtD
Terazosin—Fatigue—Epirubicin—breast cancer	6.37e-05	0.000177	CcSEcCtD
Terazosin—Pain—Epirubicin—breast cancer	6.32e-05	0.000175	CcSEcCtD
Terazosin—Constipation—Epirubicin—breast cancer	6.32e-05	0.000175	CcSEcCtD
Terazosin—Nausea—Capecitabine—breast cancer	6.3e-05	0.000175	CcSEcCtD
Terazosin—Body temperature increased—Methotrexate—breast cancer	6.24e-05	0.000173	CcSEcCtD
Terazosin—Abdominal pain—Methotrexate—breast cancer	6.24e-05	0.000173	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.23e-05	0.000173	CcSEcCtD
Terazosin—ABCB1—female reproductive system—breast cancer	6.21e-05	0.0132	CbGeAlD
Terazosin—Insomnia—Doxorubicin—breast cancer	6.19e-05	0.000172	CcSEcCtD
Terazosin—Paraesthesia—Doxorubicin—breast cancer	6.14e-05	0.00017	CcSEcCtD
Terazosin—Dyspnoea—Doxorubicin—breast cancer	6.1e-05	0.000169	CcSEcCtD
Terazosin—Feeling abnormal—Epirubicin—breast cancer	6.09e-05	0.000169	CcSEcCtD
Terazosin—Somnolence—Doxorubicin—breast cancer	6.08e-05	0.000169	CcSEcCtD
Terazosin—ABCB1—adrenal gland—breast cancer	6.06e-05	0.0129	CbGeAlD
Terazosin—Gastrointestinal pain—Epirubicin—breast cancer	6.04e-05	0.000168	CcSEcCtD
Terazosin—Dyspepsia—Doxorubicin—breast cancer	6.02e-05	0.000167	CcSEcCtD
Terazosin—Decreased appetite—Doxorubicin—breast cancer	5.95e-05	0.000165	CcSEcCtD
Terazosin—Fatigue—Doxorubicin—breast cancer	5.9e-05	0.000164	CcSEcCtD
Terazosin—ABCB1—bone marrow—breast cancer	5.86e-05	0.0124	CbGeAlD
Terazosin—Constipation—Doxorubicin—breast cancer	5.85e-05	0.000162	CcSEcCtD
Terazosin—Pain—Doxorubicin—breast cancer	5.85e-05	0.000162	CcSEcCtD
Terazosin—Abdominal pain—Epirubicin—breast cancer	5.84e-05	0.000162	CcSEcCtD
Terazosin—Body temperature increased—Epirubicin—breast cancer	5.84e-05	0.000162	CcSEcCtD
Terazosin—Hypersensitivity—Methotrexate—breast cancer	5.82e-05	0.000162	CcSEcCtD
Terazosin—Asthenia—Methotrexate—breast cancer	5.67e-05	0.000157	CcSEcCtD
Terazosin—ABCB1—female gonad—breast cancer	5.65e-05	0.012	CbGeAlD
Terazosin—Feeling abnormal—Doxorubicin—breast cancer	5.64e-05	0.000156	CcSEcCtD
Terazosin—Gastrointestinal pain—Doxorubicin—breast cancer	5.59e-05	0.000155	CcSEcCtD
Terazosin—Pruritus—Methotrexate—breast cancer	5.59e-05	0.000155	CcSEcCtD
Terazosin—Hypersensitivity—Epirubicin—breast cancer	5.45e-05	0.000151	CcSEcCtD
Terazosin—Body temperature increased—Doxorubicin—breast cancer	5.41e-05	0.00015	CcSEcCtD
Terazosin—Abdominal pain—Doxorubicin—breast cancer	5.41e-05	0.00015	CcSEcCtD
Terazosin—Diarrhoea—Methotrexate—breast cancer	5.4e-05	0.00015	CcSEcCtD
Terazosin—Asthenia—Epirubicin—breast cancer	5.3e-05	0.000147	CcSEcCtD
Terazosin—ABCB1—endocrine gland—breast cancer	5.25e-05	0.0111	CbGeAlD
Terazosin—Pruritus—Epirubicin—breast cancer	5.23e-05	0.000145	CcSEcCtD
Terazosin—Dizziness—Methotrexate—breast cancer	5.22e-05	0.000145	CcSEcCtD
Terazosin—Diarrhoea—Epirubicin—breast cancer	5.06e-05	0.00014	CcSEcCtD
Terazosin—Hypersensitivity—Doxorubicin—breast cancer	5.04e-05	0.00014	CcSEcCtD
Terazosin—Vomiting—Methotrexate—breast cancer	5.02e-05	0.000139	CcSEcCtD
Terazosin—Rash—Methotrexate—breast cancer	4.98e-05	0.000138	CcSEcCtD
Terazosin—Dermatitis—Methotrexate—breast cancer	4.98e-05	0.000138	CcSEcCtD
Terazosin—Headache—Methotrexate—breast cancer	4.95e-05	0.000137	CcSEcCtD
Terazosin—Asthenia—Doxorubicin—breast cancer	4.91e-05	0.000136	CcSEcCtD
Terazosin—Dizziness—Epirubicin—breast cancer	4.89e-05	0.000136	CcSEcCtD
Terazosin—Pruritus—Doxorubicin—breast cancer	4.84e-05	0.000134	CcSEcCtD
Terazosin—Vomiting—Epirubicin—breast cancer	4.7e-05	0.00013	CcSEcCtD
Terazosin—Nausea—Methotrexate—breast cancer	4.69e-05	0.00013	CcSEcCtD
Terazosin—Diarrhoea—Doxorubicin—breast cancer	4.68e-05	0.00013	CcSEcCtD
Terazosin—Rash—Epirubicin—breast cancer	4.66e-05	0.000129	CcSEcCtD
Terazosin—Dermatitis—Epirubicin—breast cancer	4.66e-05	0.000129	CcSEcCtD
Terazosin—Headache—Epirubicin—breast cancer	4.63e-05	0.000129	CcSEcCtD
Terazosin—Dizziness—Doxorubicin—breast cancer	4.52e-05	0.000126	CcSEcCtD
Terazosin—Nausea—Epirubicin—breast cancer	4.39e-05	0.000122	CcSEcCtD
Terazosin—Vomiting—Doxorubicin—breast cancer	4.35e-05	0.000121	CcSEcCtD
Terazosin—Rash—Doxorubicin—breast cancer	4.31e-05	0.00012	CcSEcCtD
Terazosin—Dermatitis—Doxorubicin—breast cancer	4.31e-05	0.00012	CcSEcCtD
Terazosin—Headache—Doxorubicin—breast cancer	4.28e-05	0.000119	CcSEcCtD
Terazosin—Nausea—Doxorubicin—breast cancer	4.06e-05	0.000113	CcSEcCtD
Terazosin—ABCB1—lymph node—breast cancer	3.63e-05	0.0077	CbGeAlD
Terazosin—ADRA1B—Signaling Pathways—FGF1—breast cancer	1.11e-05	9.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CSF2—breast cancer	1.11e-05	9.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—RAF1—breast cancer	1.1e-05	9.95e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2D6—breast cancer	1.1e-05	9.93e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CAV1—breast cancer	1.1e-05	9.9e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NRG1—breast cancer	1.1e-05	9.9e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CD—breast cancer	1.1e-05	9.9e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFA—breast cancer	1.1e-05	9.89e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—H2AFX—breast cancer	1.09e-05	9.83e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—IL2—breast cancer	1.09e-05	9.82e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KDR—breast cancer	1.09e-05	9.79e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—E2F1—breast cancer	1.08e-05	9.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFBR2—breast cancer	1.08e-05	9.75e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOA2—breast cancer	1.08e-05	9.75e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CB—breast cancer	1.08e-05	9.71e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ITPR1—breast cancer	1.06e-05	9.59e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ESR1—breast cancer	1.06e-05	9.54e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB4—breast cancer	1.06e-05	9.53e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT5A—breast cancer	1.06e-05	9.53e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP3—breast cancer	1.06e-05	9.53e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CB—breast cancer	1.05e-05	9.5e-05	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	1.05e-05	9.47e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—FASN—breast cancer	1.05e-05	9.45e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FN1—breast cancer	1.05e-05	9.43e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—BCHE—breast cancer	1.04e-05	9.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SPP1—breast cancer	1.04e-05	9.37e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL8—breast cancer	1.03e-05	9.33e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NFKBIA—breast cancer	1.03e-05	9.31e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC5A5—breast cancer	1.03e-05	9.3e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB3—breast cancer	1.03e-05	9.27e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGFR2—breast cancer	1.03e-05	9.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SMAD4—breast cancer	1.02e-05	9.23e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH1—breast cancer	1.02e-05	9.22e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF1R—breast cancer	1.02e-05	9.17e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL8—breast cancer	1.01e-05	9.13e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CG—breast cancer	1e-05	9.02e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KIT—breast cancer	1e-05	9.02e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—APC—breast cancer	1e-05	9.02e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HES1—breast cancer	9.99e-06	9.01e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NQO1—breast cancer	9.96e-06	8.98e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC2A1—breast cancer	9.96e-06	8.98e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PLA2G4A—breast cancer	9.93e-06	8.96e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NCOR1—breast cancer	9.93e-06	8.96e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL2—breast cancer	9.89e-06	8.92e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGF—breast cancer	9.89e-06	8.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TERT—breast cancer	9.85e-06	8.89e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CSF2—breast cancer	9.82e-06	8.86e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF1—breast cancer	9.82e-06	8.86e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—RAF1—breast cancer	9.8e-06	8.84e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NRG1—breast cancer	9.75e-06	8.79e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP3A4—breast cancer	9.71e-06	8.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—H2AFX—breast cancer	9.68e-06	8.73e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—IL2—breast cancer	9.67e-06	8.72e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—E2F1—breast cancer	9.61e-06	8.67e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—MAPK3—breast cancer	9.58e-06	8.64e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGFR1—breast cancer	9.57e-06	8.63e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CB—breast cancer	9.57e-06	8.63e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1B1—breast cancer	9.55e-06	8.61e-05	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	9.5e-06	8.56e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HIF1A—breast cancer	9.42e-06	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BRAF—breast cancer	9.4e-06	8.48e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HSP90AA1—breast cancer	9.36e-06	8.44e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SPP1—breast cancer	9.23e-06	8.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—LEP—breast cancer	9.2e-06	8.3e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL8—breast cancer	9.19e-06	8.29e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IGF1—breast cancer	9.16e-06	8.26e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT2—breast cancer	9.15e-06	8.25e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB3—breast cancer	9.13e-06	8.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGFR2—breast cancer	9.12e-06	8.22e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CAV1—breast cancer	9.11e-06	8.22e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—breast cancer	9.11e-06	8.22e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOA1—breast cancer	9.11e-06	8.21e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KDR—breast cancer	9.01e-06	8.13e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP19A1—breast cancer	8.97e-06	8.09e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—STK11—breast cancer	8.97e-06	8.09e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CD—breast cancer	8.79e-06	7.93e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL2—breast cancer	8.78e-06	7.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ESR1—breast cancer	8.78e-06	7.92e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TERT—breast cancer	8.75e-06	7.89e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—breast cancer	8.71e-06	7.85e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SERPINE1—breast cancer	8.7e-06	7.84e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FN1—breast cancer	8.68e-06	7.82e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—KRAS—breast cancer	8.61e-06	7.76e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NFKBIA—breast cancer	8.57e-06	7.73e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGFR1—breast cancer	8.5e-06	7.66e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH1—breast cancer	8.49e-06	7.66e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HIF1A—breast cancer	8.37e-06	7.55e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—COMT—breast cancer	8.34e-06	7.52e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTP1—breast cancer	8.3e-06	7.49e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOS3—breast cancer	8.3e-06	7.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CG—breast cancer	8.3e-06	7.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KIT—breast cancer	8.3e-06	7.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—APC—breast cancer	8.3e-06	7.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGF—breast cancer	8.21e-06	7.4e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HMOX1—breast cancer	8.19e-06	7.39e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—LEP—breast cancer	8.17e-06	7.37e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ITPR1—breast cancer	8.17e-06	7.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CAV1—breast cancer	8.1e-06	7.3e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KDR—breast cancer	8.01e-06	7.22e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAPK3—breast cancer	7.95e-06	7.17e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—breast cancer	7.91e-06	7.13e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MDM2—breast cancer	7.88e-06	7.1e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAF1—breast cancer	7.85e-06	7.08e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RELA—breast cancer	7.82e-06	7.05e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BRAF—breast cancer	7.8e-06	7.04e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ESR1—breast cancer	7.8e-06	7.04e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB2—breast cancer	7.77e-06	7e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TYMS—breast cancer	7.72e-06	6.96e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FN1—breast cancer	7.71e-06	6.95e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CB—breast cancer	7.66e-06	6.91e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MTOR—breast cancer	7.66e-06	6.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTM1—breast cancer	7.63e-06	6.88e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PLA2G4A—breast cancer	7.63e-06	6.88e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOR1—breast cancer	7.63e-06	6.88e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	7.61e-06	6.87e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IGF1—breast cancer	7.6e-06	6.86e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT2—breast cancer	7.6e-06	6.85e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—breast cancer	7.56e-06	6.82e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	7.54e-06	6.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KIT—breast cancer	7.37e-06	6.65e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—APC—breast cancer	7.37e-06	6.65e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	7.37e-06	6.65e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL8—breast cancer	7.37e-06	6.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HRAS—breast cancer	7.32e-06	6.6e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GPX1—breast cancer	7.31e-06	6.59e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CD—breast cancer	7.3e-06	6.58e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGF—breast cancer	7.29e-06	6.57e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1A1—breast cancer	7.23e-06	6.52e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—breast cancer	7.23e-06	6.52e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SERPINE1—breast cancer	7.22e-06	6.51e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1B—breast cancer	7.19e-06	6.49e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ERCC2—breast cancer	7.17e-06	6.47e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—KRAS—breast cancer	7.15e-06	6.44e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKT1—breast cancer	7.12e-06	6.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	7.06e-06	6.37e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CASP3—breast cancer	7.05e-06	6.36e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2—breast cancer	7.04e-06	6.35e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—breast cancer	7e-06	6.32e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BRAF—breast cancer	6.93e-06	6.25e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOS3—breast cancer	6.89e-06	6.22e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—breast cancer	6.86e-06	6.19e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—JUN—breast cancer	6.85e-06	6.18e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CTNNB1—breast cancer	6.8e-06	6.13e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF1—breast cancer	6.75e-06	6.09e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT2—breast cancer	6.75e-06	6.08e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—MTHFR—breast cancer	6.74e-06	6.08e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—breast cancer	6.72e-06	6.06e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MMP9—breast cancer	6.66e-06	6.01e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—breast cancer	6.64e-06	5.99e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PTEN—breast cancer	6.62e-06	5.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—breast cancer	6.56e-06	5.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MDM2—breast cancer	6.54e-06	5.9e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAF1—breast cancer	6.52e-06	5.88e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RELA—breast cancer	6.49e-06	5.85e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	6.48e-06	5.85e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK8—breast cancer	6.48e-06	5.84e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKT1—breast cancer	6.46e-06	5.83e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB2—breast cancer	6.45e-06	5.81e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	6.42e-06	5.79e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	6.41e-06	5.78e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MTOR—breast cancer	6.36e-06	5.74e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CB—breast cancer	6.36e-06	5.74e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—KRAS—breast cancer	6.35e-06	5.72e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CAV1—breast cancer	6.22e-06	5.61e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SRC—breast cancer	6.14e-06	5.54e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOS3—breast cancer	6.12e-06	5.52e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL8—breast cancer	6.11e-06	5.51e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HRAS—breast cancer	6.07e-06	5.48e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—breast cancer	5.98e-06	5.39e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	5.97e-06	5.38e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STAT3—breast cancer	5.92e-06	5.34e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	5.91e-06	5.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CASP3—breast cancer	5.85e-06	5.28e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2—breast cancer	5.84e-06	5.27e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	5.83e-06	5.26e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—breast cancer	5.81e-06	5.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MDM2—breast cancer	5.81e-06	5.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAF1—breast cancer	5.79e-06	5.22e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RELA—breast cancer	5.76e-06	5.2e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB2—breast cancer	5.73e-06	5.16e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—breast cancer	5.7e-06	5.14e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JUN—breast cancer	5.68e-06	5.13e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CG—breast cancer	5.67e-06	5.11e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK3—breast cancer	5.66e-06	5.1e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	5.65e-06	5.1e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MTOR—breast cancer	5.65e-06	5.1e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	5.64e-06	5.09e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MMP9—breast cancer	5.53e-06	4.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	5.51e-06	4.97e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—breast cancer	5.5e-06	4.96e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PTEN—breast cancer	5.5e-06	4.96e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFB1—breast cancer	5.49e-06	4.95e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL8—breast cancer	5.43e-06	4.9e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HRAS—breast cancer	5.39e-06	4.87e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—breast cancer	5.38e-06	4.85e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK8—breast cancer	5.38e-06	4.85e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKT1—breast cancer	5.36e-06	4.84e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	5.3e-06	4.78e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	5.25e-06	4.73e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP3—breast cancer	5.2e-06	4.69e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2—breast cancer	5.19e-06	4.68e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—breast cancer	5.16e-06	4.66e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SRC—breast cancer	5.1e-06	4.6e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KRAS—breast cancer	5.09e-06	4.59e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—breast cancer	5.06e-06	4.56e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JUN—breast cancer	5.05e-06	4.55e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	5.01e-06	4.52e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CD—breast cancer	4.98e-06	4.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—breast cancer	4.97e-06	4.48e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALB—breast cancer	4.92e-06	4.43e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT3—breast cancer	4.92e-06	4.43e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP9—breast cancer	4.91e-06	4.43e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	4.89e-06	4.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PTEN—breast cancer	4.88e-06	4.4e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK8—breast cancer	4.78e-06	4.31e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKT1—breast cancer	4.76e-06	4.3e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NOS3—breast cancer	4.7e-06	4.24e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK3—breast cancer	4.7e-06	4.24e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	4.67e-06	4.21e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—breast cancer	4.57e-06	4.12e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFB1—breast cancer	4.56e-06	4.11e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SRC—breast cancer	4.53e-06	4.08e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—breast cancer	4.52e-06	4.08e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—breast cancer	4.47e-06	4.03e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—breast cancer	4.41e-06	3.98e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT3—breast cancer	4.37e-06	3.94e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CB—breast cancer	4.34e-06	3.92e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HRAS—breast cancer	4.32e-06	3.9e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTGS2—breast cancer	4.3e-06	3.88e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KRAS—breast cancer	4.22e-06	3.81e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK3—breast cancer	4.17e-06	3.76e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—breast cancer	4.14e-06	3.73e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—breast cancer	4.06e-06	3.66e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFB1—breast cancer	4.05e-06	3.65e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.97e-06	3.58e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	3.88e-06	3.5e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT1—breast cancer	3.82e-06	3.44e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTEN—breast cancer	3.75e-06	3.38e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—breast cancer	3.75e-06	3.38e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KRAS—breast cancer	3.75e-06	3.38e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HRAS—breast cancer	3.59e-06	3.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	3.44e-06	3.11e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—breast cancer	3.43e-06	3.1e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—breast cancer	3.33e-06	3.01e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HRAS—breast cancer	3.19e-06	2.87e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT1—breast cancer	3.17e-06	2.86e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—breast cancer	3.05e-06	2.75e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.81e-06	2.54e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—breast cancer	2.65e-06	2.39e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKT1—breast cancer	2.16e-06	1.95e-05	CbGpPWpGaD
